Evaluation of mRNA Expression Profile of ABCG2/BCRP in Childhood Acute Lymphoblastic Leukemia

Introduction: Multidrug resistance (MDR) is the main obstacle against treatment of acute lymphoblastic leukemia (ALL). ATP-binding cassette transporters function is mentioned as one of the most effective factors on MDR development. Though, there are many evidences on interference of ABCG2/BCRP, one of the outstanding members of this superfamly, in MDR occurrence, the expression effect of this gene on blasts of ALL patients is unknown yet. Methods: In this study, we used Real-Time PCR technique in order to investigate the relative expression of ABCG2/BCRP mRNA in 1-17 year old children with ALL. Peripheral or bone marrow blood samples from 28 new case leukemic and 15 control children were investigated with cooperation of Seyyedo-Shohada hospital in Isfahan,. Minimal Residual Disease (MRD) was evaluated as quality of patient response to chemotherapy. Results: Profile of ABCG2/BCRP mRNA expression did not have any significant difference in new case ALL patients in comparison with control children. On the other hand, comparison of two groups of MRD + and MRD - patients showed no difference in ABCG2/BCRP expression level. The level of ABCG2 expression was not associated with immunophenotype of ALL or known prognosis factors for this type of leukemia. Conclusion: Results of this study showed no effect of ABCG2/BCRP expression level on MDR development in ALL. Accordingly, clinical value of ABCG2/BCRP expression profile determination was rejected as the prognosis value for childhood ALL in our geographical area.

[1]  M. Litzow.  Acute lymphoblastic leukemia , 2014 .

[2]  D. Ross,et al.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. , 2012, Biochemical pharmacology.

[3]  S. Lydersen,et al.  Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia , 2011, Pediatric blood & cancer.

[4]  D. Hoelzer,et al.  Modern therapy of acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Scrideli,et al.  mRNA expression profile of multidrug resistance genes in childhood acute lymphoblastic leukemia. Low expression levels associated with a higher risk of toxic death , 2009, Pediatric blood & cancer.

[6]  C. Pui,et al.  The Eleventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Ponte di Legno, Italy, May 6-7, 2009 , 2009, Leukemia.

[7]  Marilyn E. Morris,et al.  Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.

[8]  S. D. de Morais,et al.  Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. , 2009, Pharmacological research.

[9]  D. Rees,et al.  ABC transporters: the power to change , 2009, Nature Reviews Molecular Cell Biology.

[10]  K. Locher.  Structure and mechanism of ATP-binding cassette transporters , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.

[11]  V. P. Savitski,et al.  Expression of MDR1, LRP, BCRP and Bcl-2 genes at diagnosis of childhood all: comparison with MRD status after induction therapy. , 2008, Experimental oncology.

[12]  V. Ling,et al.  MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. , 2008, Experimental hematology.

[13]  T. Szczepański,et al.  Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia , 2007, Journal of Cancer Research and Clinical Oncology.

[14]  D. Koliouskas,et al.  Expression of Multidrug Resistance 1 (MDR1), Multidrug Resistance-Related Protein 1 (MRP1), Lung Resistance Protein (LRP), and Breast Cancer Resistance Protein (BCRP) Genes and Clinical Outcome in Childhood Acute Lymphoblastic Leukemia , 2007, International journal of hematology.

[15]  D. Steinbach,et al.  ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? , 2007, Leukemia.

[16]  A. von Eckardstein,et al.  Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. , 2006, Biochimica et biophysica acta.

[17]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[18]  J. Philippé,et al.  Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. , 2006, European journal of cancer.

[19]  Mariël Brok,et al.  Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps , 2005, Cancer biology & therapy.

[20]  O. Legrand,et al.  Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.

[21]  M. Filipits.  Mechanisms of cancer: multidrug resistance , 2004 .

[22]  W. Greco,et al.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease‐free survival , 2004, British journal of haematology.

[23]  W. Greco,et al.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function , 2004, Leukemia.

[24]  T. Uchida,et al.  Comparative analysis of ATP‐binding cassette (ABC) transporter gene expression levels in peripheral blood leukocytes and in liver with hepatocellular carcinoma , 2004, Cancer science.

[25]  Y. Pommier,et al.  ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases , 2004, International journal of cancer.

[26]  W. Kamps,et al.  The role of breast cancer resistance protein in acute lymphoblastic leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  M. Andreeff,et al.  Low levels of ABCG2 expression in adult AML blast samples. , 2002, Blood.

[28]  I. Catalá,et al.  Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.

[29]  D. Steinbach,et al.  BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia , 2002, Leukemia.

[30]  D. Steinbach,et al.  Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia , 2002, British journal of haematology.

[31]  J. Styczyński,et al.  In Vitro Drug Resistance Profiles of Adult Acute Lymphoblastic Leukemia: Possible Explanation for Difference in Outcome to Similar Therapeutic Regimens , 2002, Leukemia & lymphoma.

[32]  A Rzhetsky,et al.  The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Journal of lipid research.

[33]  J. M. Nørgaard,et al.  Biology of multiple drug resistance in acute leukemia. , 2000, International journal of hematology.

[34]  R. Pieters,et al.  TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. , 2000, Blood.

[35]  E. Hudson,et al.  The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.

[36]  Va Medical.  Breast cancer resistance protein(BCRP/ABCG2):its role in multidrug resistance and regulation of its gene expression , 2012 .

[37]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[38]  J. Roganovic,et al.  Epidemiology of childhood cancer. , 1999, IARC scientific publications.

[39]  J. Chessells.  Acute lymphoblastic leukemia. , 1982, Seminars in hematology.